March 16, 2020
•First in a Complete Family of Genetic Tests
•Test detects variants in inherited conditions
•Test available to physicians and patients starting immediately
DELRAY BEACH, FL – Genetics Institute of America today announced completion of validation studies and the launch of its GIAnomics®-CGx test, the first test in its new GIAnomics® line of genetic tests.
The GIAnomics®-CGx test provides improved detection of pathogenic variants for inherited genetic disorders while reducing turn-around-times. The GIAnomics®-CGx test panel includes well known genes such as BRCA1 and BRCA2 as well as other less publicized genes to provide actionable information to physicians and patients.
Genetics Institute of America selected the ThermoFischer Scientific Ion GeneStudio S5 Next Generation Sequencing System and Ion AmpliSeq assay design to launch the GIAnomics®-CGx test.
“We have a strong working relationship with ThermoFischer in both the research and clinical spaces”, said Holly Magliochetti, CEO and Founder.
The GIAnomics®-CGx test is the first in a new, full family of genetic tests to be validated. Genetics Institute of America has seven (7) additional tests in the GIAnomics® development and validation pipeline. The test is available to physicians and patients starting immediately.